Edward M. Kaye
Net Worth

Last updated:

What is Edward M. Kaye net worth?

The estimated net worth of Dr. Edward M. Kaye is at least $7,769,311 as of 6 Sep 2025. He owns shares worth $1,132,496 as insider, has earned $888,515 from insider trading and has received compensation worth at least $5,748,300 in Sarepta Therapeutics, Inc. and Stoke Therapeutics, Inc..

What is the salary of Edward M. Kaye?

Dr. Edward M. Kaye salary is $958,050 per year as Chief Executive Officer & Director in Stoke Therapeutics, Inc..

What stocks does Edward M. Kaye currently own?

As insider, Dr. Edward M. Kaye owns shares in one company:

Company Title Shares Price per share Total value
Stoke Therapeutics, Inc. (STOK) Chief Executive Officer & Director 61,885 $18.3 $1,132,496

What does Stoke Therapeutics, Inc. do?

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

STOK logo
STOK
Stoke Therapeutics, Inc.
$18.3

Edward M. Kaye insider trading

Stoke Therapeutics, Inc.

Dr. Edward M. Kaye has made 9 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 6,786 units of STOK stock worth $88,157 on 9 Dec 2024.

The largest trade he's ever made was exercising 50,000 units of STOK stock on 16 Dec 2019. As of 6 Sep 2025 he still owns at least 61,885 units of STOK stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 6,786 $12.99 $88,157
Sale
Common Stock 6,170 $12.78 $78,840
Option
Performance Stock Units 26,500 N/A N/A
Option
Common Stock 26,250 N/A N/A
Option
Performance Stock Units 26,250 N/A N/A
Option
Common Stock 26,500 N/A N/A
Option
Restricted Stock Unit (RSU) 21,591 N/A N/A
Option
Common Stock 21,591 N/A N/A
Sale
Common Stock 39,686 $15.39 $610,768
Sale
Common Stock 2,664 $16.05 $42,747
Sale
Common Stock 11,150 $6.1 $68,004
Option
Restricted Stock Units 35,500 N/A N/A
Option
Common Stock 35,500 N/A N/A
Option
Employee Stock Option (right to buy) 15,000 $0.6 $9,000
Option
Common Stock 15,000 $0.6 $9,000
Option
Employee Stock Option (right to buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 5,194 N/A N/A
Sale
Common Stock 19,806 N/A N/A
Sale
Common Stock 12,152 N/A N/A
Sale
Common Stock 12,848 N/A N/A
Option
Common Stock 50,000 N/A N/A
Option
Employee Stock Option (right to buy) 50,000 N/A N/A

Sarepta Therapeutics key executives

Sarepta Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Diane L. Berry Senior Vice President of Global Health Policy and Gov. & Patient Affairs
  • Dr. Edward M. Kaye Advisor
  • Dr. Gilmore O'Neill M.D. (60) Executive Vice President of R&D and Chief Medical Officer
  • Dr. Louise Rodino-Klapac Ph.D. Senior Vice President of Gene Therapy
  • Mr. David Tyronne Howton Jr. (53) Executive Vice President, Gen. Counsel & Corporation Sec.
  • Mr. Douglas S. Ingram (62) Pres, Chief Executive Officer & Director
  • Mr. Ian M. Estepan Senior Vice President of Corporation Affairs & Chief of Staff
  • Mr. Joseph Bratica Controller, Vice President and Interim Principal Financial & Accounting Officer
  • Mr. William F. Ciambrone (61) Executive Vice President of Technical Operations
  • Ms. Joan Nickerson M.B.A. Senior Vice President of HR